The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
 
Fiona Simpkins
Consulting or Advisory Role - AstraZeneca; Zentalis
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Instil Bio (Inst); Repare Therapeutics (Inst); Sierra Oncology (Inst)
 
Dimitrios Nasioudis
Employment - Janssen (I); Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
 
Stephanie L. Wethington
Employment - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Lainie P. Martin
Consulting or Advisory Role - Elucida Oncology; Immunogen; Myriad Genetics; Sutro Biopharma
Research Funding - Agenus (Inst); AstraZeneca (Inst); Immunogen (Inst); Mersana (Inst); Shattuck Labs (Inst); Sutro bioPharma (Inst); Xencor (Inst)
 
Janos Laszlo Tanyi
No Relationships to Disclose
 
Nawar A. Latif
No Relationships to Disclose
 
Drew A. Torigian
Other Relationship - Quantitative Radiology Solutions
 
Dalia K. Omran
No Relationships to Disclose
 
Diego Rodriguez
No Relationships to Disclose
 
Simon Smith
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Emma Dean
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca (I); AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Ronny Drapkin
No Relationships to Disclose
 
Ie-Ming Shih
No Relationships to Disclose
 
Eric J Brown
No Relationships to Disclose
 
Wei-Ting Hwang
Employment - Janssen (I)
Research Funding - Novartis
 
Deborah Kay Armstrong
Consulting or Advisory Role - Johnson & Johnson/Janssen; Teon Therapeutics
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Pfizer (Inst); Syndax (Inst)
Other Relationship - AstraZeneca; AstraZeneca; AstraZeneca
 
Stephanie Gaillard
Consulting or Advisory Role - Immunogen; Merck; Verastem
Research Funding - AstraZeneca (Inst); Blueprint Pharmaceutic (Inst); Clovis Oncology (Inst); Compugen (Inst); Genentech/Roche (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - United States Patent Nos 10,258,604 & 10,905,659, licensed by Duke University to Sermonix (Inst)
 
Robert Lawrence Giuntoli
No Relationships to Disclose
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron; Zentalis
Research Funding - 2X Oncology (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)